Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma.

Artzenroth, Jule Cecilia; Tintelnot, Joseph; Haag, Georg Martin; Gökkurt, Eray; Steffens, Johann; Stein, Alexander

Artzenroth, Jule Cecilia; Tintelnot, Joseph; Haag, Georg Martin; Gökkurt, Eray; Steffens, Johann; Stein, Alexander.

Afiliação

Artzenroth JC; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tintelnot J; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Haag GM; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Gökkurt E; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Steffens J; Hämatologisch-Onkologische Praxis Eppendorf, Hamburg, Germany.
Stein A; Radiologische Praxis am Israelitisches Krankenhaus, Hamburg, Germany.

Oncol Res Treat ; 46(7-8): 320-325, 2023.

Article em En | MEDLINE | ID: mdl-37231946

Assuntos

Adenocarcinoma; Ribose; Masculino; Humanos; Antígeno B7-H1/metabolismo; Receptor de Morte Celular Programada 1; Hibridização in Situ Fluorescente; Adenocarcinoma/patologia; DNA Helicases; Proteínas Nucleares/genética; Fatores de Transcrição/genética

Palavras-chave

Esophagogastric adenocarcinoma; Poly-(ARD-Ribose) polymerase inhibitors; Programmed cell death protein 1/L1 inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ribose / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google